Literature DB >> 34208989

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.

Steffen Bayerschmidt1, Christian Uprimny1, Alexander Stephan Kroiss1, Josef Fritz2, Bernhard Nilica1, Hanna Svirydenka1, Clemens Decristoforo1, Elisabeth von Guggenberg1, Wolfgang Horninger3, Irene Johanna Virgolini1.   

Abstract

BACKGROUND: 68Ga-PSMA-11 PET/CT is a promising method for the assessment of local recurrence (LR) in prostate cancer (PCa) patients. The aim of this study was to evaluate the diagnostic performance of early 68Ga-PSMA-11 PET imaging in comparison to 68Ga-PSMA-11 PET imaging 60 min post-injection (p.i.) in the detection of LR in patients with biochemical recurrence (BR) of prostate carcinoma. <br> MATERIALS AND METHODS: 190 image sets of patients with BR in PCa who underwent 68Ga-PSMA-11 PET/CT were assessed retrospectively (median prostate specific antigen (PSA) value, 0.70 ng/mL (range, 0.1-105.6 ng/mL)). Patients received an early static scan of the pelvic area (median, 248 s p.i. (range, 56-923 s)) and a whole-body scan 60 min p.i. (median, 64 min p.i. (range, 45-100 min)) with intravenous administration of 20 mg furosemide i.v. at the time of tracer application, followed by intravenous hydration with 500 mL of sodium chloride (NaCl 0.9%). Assessment was based on visual analysis and calculation of the maximum standardized uptake value (SUVmax) of the pathologic lesions present in the prostate fossa found in the early PET imaging and 60 min PET scans. The scans were characterized as negative, positive, or equivocal. The results were compared, and the combination of early and 60 min p.i. imaging was evaluated. <br> RESULTS: Image assessment resulted in 30 (15.8%) positive, 17 (8.9%) equivocal, and 143 (75.3%) negative findings in early scans, and 28 (14.7%) positive, 25 (13.2%) equivocal, and 137 (72.1%) negative findings of LR in 60 min p.i. images. For combined image analysis, 33 (17.4%) cases were positive and 20 (10.5%) were equivocal. There was no statistical significance between the number of positive (p = 0.815), negative (p = 0.327), and equivocal (p = 0.152) findings. Furthermore, the combination of both scans showed no statistically significant differences for the positive and negative findings (p = 0.063). The median SUVmax was 4.9 (range, 2.0-55.2) for positive lesions in the early scans and 8.0 (range, 2.1-139.9) in the scans 60 min p.i. The median SUVmax for bladder activity was 2.5 (range, 0.9-12.2) in the early scans and 8.2 (range, 1.8-27.6) in the scans 60 min p.i. <br> CONCLUSION: Early static imaging additional to 68Ga-PSMA-11 PET images acquired 60 min p.i. has limited value in patients prepared with furosemide and hydration, and showed no statistically significant change in the detection rate (DR) of LR and the number of equivocal findings. Based on our results, in departments following a protocol with forced diuresis, including furosemide, additional early static imaging cannot be routinely recommended for the assessment of BR in PCa patients.

Entities:  

Keywords:  68Ga-PSMA-11; PET; PET/CT; biochemical recurrence; early imaging; furosemide; local recurrence; prostate cancer; prostate specific membrane antigen

Year:  2021        PMID: 34208989     DOI: 10.3390/diagnostics11071191

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  17 in total

1.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2000-12-20       Impact factor: 56.272

2.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

3.  Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer.

Authors:  Niall Fennessy; Jonathan Lee; Jane Shin; Bao Ho; Syed Aman Ali; Royce Paschkewitz; Louise Emmett
Journal:  J Med Imaging Radiat Oncol       Date:  2017-06-17       Impact factor: 1.735

4.  Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI.

Authors:  Martin T Freitag; Jan P Radtke; Ali Afshar-Oromieh; Matthias C Roethke; Boris A Hadaschik; Martin Gleave; David Bonekamp; Klaus Kopka; Matthias Eder; Thorsten Heusser; Marc Kachelriess; Kathrin Wieczorek; Christos Sachpekidis; Paul Flechsig; Frederik Giesel; Markus Hohenfellner; Uwe Haberkorn; Heinz-Peter Schlemmer; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-17       Impact factor: 9.236

5.  68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.

Authors:  Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-01-31       Impact factor: 9.236

6.  Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Reşit Akyel; Jamal Nematyazar; Aslan Aygun; Metin Halac; Zubeyir Talat; Ahmet Araman
Journal:  Nucl Med Commun       Date:  2015-06       Impact factor: 1.690

7.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 8.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

9.  68Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol.

Authors:  Fabian Haupt; Lotte Dijkstra; Ian Alberts; Christos Sachpekidis; Viktor Fech; Silvan Boxler; Tobias Gross; Tim Holland-Letz; Helle D Zacho; Uwe Haberkorn; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-01       Impact factor: 9.236

10.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Authors:  Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

View more
  2 in total

1.  On the Way for Patients with Prostate Cancer to the Best Use of PSMA.

Authors:  Finn Edler von Eyben; Glenn Bauman; Daniel S Kapp; Irene Virgolini; Giovanni Paganelli
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

2.  What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.

Authors:  Hsiou-Ting Kuo; Kuo-Shyan Lin; Zhengxing Zhang; Chengcheng Zhang; Helen Merkens; Ruiyan Tan; Aron Roxin; Carlos F Uribe; François Bénard
Journal:  Theranostics       Date:  2022-08-21       Impact factor: 11.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.